Astellas Pharma Inc. Stock

Equities

4503

JP3942400007

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-04-19 am EDT 5-day change 1st Jan Change
1,480 JPY +1.02% Intraday chart for Astellas Pharma Inc. -5.76% -12.19%
Sales 2024 * 1,571B 10.15B Sales 2025 * 1,667B 10.78B Capitalization 2,655B 17.16B
Net income 2024 * 43.83B 283M Net income 2025 * 136B 877M EV / Sales 2024 * 2.01 x
Net Debt 2024 * 503B 3.25B Net Debt 2025 * 448B 2.9B EV / Sales 2025 * 1.86 x
P/E ratio 2024 *
65.7 x
P/E ratio 2025 *
19.5 x
Employees 14,484
Yield 2024 *
4.73%
Yield 2025 *
5.05%
Free-Float 98.83%
More Fundamentals * Assessed data
Dynamic Chart
Japan Inc makes a renewed U.S. push as China fears mount RE
Middle East Tensions Blunt Asian Stock Markets Excepting China MT
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March MT
Japan's Nikkei sags as Iran attack, Wall Street sell-off sour sentiment RE
Japan's Nikkei drops 1% as Iran attack, Wall Street sell-off fuel risk aversion RE
Astellas Pharma Inc. Provides Impairment Loss for Intangible Assets Guidance for the Fourth Quarter 2023 CI
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024 CI
Jefferies Adjusts Astellas Pharma’s Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy MT
U.S. FDA Accepts Astellas? Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy CI
Pfizer, Astellas' Combination Therapy Application For Bladder Cancer Accepted in China MT
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer CI
Astellas Pharma Inc.'s Vyloy?? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer CI
Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI? in Additional Recurrent Early Prostate Cancer Treatment Setting CI
Bayer to seek approval for menopausal relief drug after third trial win RE
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas CI
More news

Latest transcript on Astellas Pharma Inc.

1 day+1.02%
1 week-5.76%
Current month-9.92%
1 month-10.08%
3 months-13.42%
6 months-21.60%
Current year-12.19%
More quotes
1 week
1 426.00
Extreme 1426
1 524.50
1 month
1 426.00
Extreme 1426
1 696.50
Current year
1 426.00
Extreme 1426
1 801.50
1 year
1 426.00
Extreme 1426
2 360.50
3 years
1 426.00
Extreme 1426
2 360.50
5 years
1 375.00
Extreme 1375
2 360.50
10 years
1 100.00
Extreme 1100
2 360.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 86-03-31
Director of Finance/CFO 52 Oct. 31
Chairman 63 86-03-31
Members of the board TitleAgeSince
Chairman 63 86-03-31
Chief Executive Officer 61 86-03-31
Director/Board Member 68 19-05-31
More insiders
Date Price Change Volume
24-04-19 1,480 +1.02% 7,909,200
24-04-18 1,466 -0.07% 6,445,400
24-04-17 1,466 +1.03% 9,854,500
24-04-16 1,452 +0.38% 17,781,200
24-04-15 1,446 -7.96% 30,231,300

Delayed Quote Japan Exchange, April 19, 2024 at 02:00 am EDT

More quotes
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,480 JPY
Average target price
2,075 JPY
Spread / Average Target
+40.16%
Consensus